CD20-binding immunotoxins for inducing cellular internalization and methods using same
First Claim
1. A CD20-binding protein comprising the amino acid sequence shown in SEQ ID NO:
- 4 or SEQ ID NO;
12.
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides CD20-binding proteins that bind to and rapidly internalize CD20 antigens from a cell surface location to the interior of a cell. CD20-binding proteins of the invention comprise a CD20 binding region and a Shiga toxin effector region. Certain of the disclosed CD20-binding proteins kill cells that express CD20 on their surface. Further, the presently disclosed CD20-binding proteins can comprise additional exogenous materials and are capable of targeted delivery of these additional exogenous materials into the interior of CD20 expressing cells. Such additional materials may include peptides, antigens, enzymes, and polynucleotides. These CD20-binding proteins have uses in methods of internalizing themselves, targeted killing of CD20 expressing cells, delivering exogenous materials into CD20 expressing cells, and treating a variety of diseases involving CD20 expressing cells, such as cancers and immune disorders.
15 Citations
40 Claims
-
1. A CD20-binding protein comprising the amino acid sequence shown in SEQ ID NO:
- 4 or SEQ ID NO;
12. - View Dependent Claims (2)
- 4 or SEQ ID NO;
-
3. A CD20-binding protein consisting essentially of the amino acid sequence shown in SEQ ID NO:
- 4 or SEQ ID NO;
12. - View Dependent Claims (4)
- 4 or SEQ ID NO;
-
5. A pharmaceutical composition comprising
(i) a CD20-binding protein comprising the amino acid sequence shown in SEQ ID NO: - 4 or SEQ ID NO;
12; and(ii) at least one pharmaceutically acceptable excipient or carrier. - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13)
- 4 or SEQ ID NO;
-
14. A pharmaceutical composition comprising
(i) a CD20-binding protein consisting essentially of the amino acid sequence shown in SEQ ID NO: - 4 or SEQ ID NO;
12; and(ii) at least one pharmaceutically acceptable excipient or carrier. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22)
- 4 or SEQ ID NO;
-
23. A composition comprising
(i) a CD20-binding protein comprising the amino acid sequence shown in SEQ ID NO: - 4 or SEQ ID NO;
12; and(ii) a solvent or salt. - View Dependent Claims (24, 25, 26, 27, 28, 29, 30, 31)
- 4 or SEQ ID NO;
-
32. A composition comprising
(i) a CD20-binding protein consisting essentially of the amino acid sequence shown in SEQ ID NO: - 4 or SEQ ID NO;
12; and(ii) a solvent or salt. - View Dependent Claims (33, 34, 35, 36, 37, 38, 39, 40)
- 4 or SEQ ID NO;
Specification